Roots in Rehabilitation
Fourier was founded in 2015 and started with exoskeletons and rehabilitation robotics. The company lists more than 2,000 institutions in over 40 countries as users of its entire portfolio. This customer base distinguishes Fourier from humanoid start-ups without an existing product business.
Rehabilitation requires safe human-machine interaction, force control, and clinically structured procedures. Part of this experience is transferable to humanoid and assistive systems.
The GRx Series
GR-1 and GR-2 form the earlier generations of the humanoid platform. GR-3 is positioned as a care bot with interaction through speech, vision, and touch; GR-3C emphasizes more robust functional applications. N1 targets research and development as a more open system.
The technical documentation of GR-3 mentions, among other things, 55 degrees of freedom, hot-swap batteries, and approximately three hours of running time. Such data is useful, but says little about the quality of autonomous tasks.
Health, Service, and Research
Fourier can test humanoid systems through existing relationships with clinics and research institutions. For care and companion applications, however, data protection, acceptance, liability, and evidence of actual benefit are particularly important.
A friendly design can facilitate interaction but should not be confused with emotional understanding. Capabilities must be described transparently.
Editorial Classification
Fourier is a substantial robotics provider with a credible health and research base. The Atlas positions the company as an established provider, without automatically deriving an equally high maturity for all humanoids from this.
Assessment of development status
Rehabilitation systems are used internationally. GR-1, GR-2, and GR-3 are offered as products or development platforms; their readiness for deployment varies between research, service, and emerging applications.